Compare Diamondback Energy Inc (FANG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Diamondback Energy Inc trades at $189.95 (market cap $53.38B), while State Street SPDR S&P Biotech ETF trades at $153.94. The key difference: Diamondback Energy Inc pays a 2.32% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Diamondback Energy Inc nearer its low. Which is the better fit depends on your goals.
| FANG | XBI | |
|---|---|---|
Market Cap | $53.38B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $213.69 | $164.28 |
52-Week Low | $134.53 | $85.16 |
Enterprise Value | $67.11B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $190.69, showing slight daily weakness but maintaining a bullish technical outlook with strong analyst support. The company demonstrates solid revenue growth reaching $14.93B in 2025, though net margins have compressed to 1.88%. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending. The stock benefits from overwhelming analyst consensus with 90% buy ratings and a $234.50 price target representing 23% upside potential.
FANG presents a compelling growth story with expanding operations and strong cash generation, though investors face margin compression risks amid volatile energy markets. The stock's elevated P/E ratio of 193.63 reflects growth expectations, while technical indicators suggest near-term support around $189. Institutional sentiment remains positive with upcoming Q2 earnings on August 3, 2026, serving as the next key catalyst.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
